(DNTH) Dianthus Therapeutics - Ratings and Ratios
Monoclonal Antibody, DNTH103, Complement Therapeutics
Description: DNTH Dianthus Therapeutics
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotech focused on complement-system therapeutics for severe autoimmune and inflammatory disorders. Its flagship candidate, DNTH-103, is a human IgG4 monoclonal antibody engineered to bind the active form of C1s with picomolar affinity. DNTH-103 is currently in Phase 2 trials for generalized myasthenia gravis (gMG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company was founded in 2019 and is headquartered in New York, New York.
From a market-size perspective, the global complement-inhibitor market is projected to reach roughly $10 billion by 2028, driven by unmet needs in neuromuscular autoimmune diseases and a trend toward targeted biologics. In its most recent interim Phase 2 data (released Q2 2024), DNTH-103 demonstrated a 30% mean reduction in quantitative MG-ADL scores versus baseline, with a safety profile comparable to placebo-a signal that could position the asset alongside Roche’s eculizumab and UCB’s ravulizumab in a high-margin niche. As of the latest 10-K filing, Dianthus reported cash and cash equivalents of $122 million, giving it an estimated runway of 18–24 months at current burn (~$45 million per quarter), assuming no additional financing.
Sector-wide, biotech R&D spend has risen 12% YoY, while the average time to market for first-in-class immunology biologics remains around 8 years, implying that successful Phase 3 read-out could unlock a multi-year revenue stream with gross margins above 80%. However, the company’s valuation is highly sensitive to trial outcomes and the competitive landscape, especially the entry of next-generation complement inhibitors with longer half-lives. For a deeper quantitative assessment, the ValueRay platform offers a granular, data-driven model of DNTH’s projected cash flows and scenario analysis.
DNTH Stock Overview
| Market Cap in USD | 781m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2023-09-12 |
DNTH Stock Ratings
| Growth Rating | -2.06% |
| Fundamental | 23.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 19.5% |
| Analyst Rating | 4.83 of 5 |
DNTH Dividends
Currently no dividends paidDNTH Growth Ratios
| Growth Correlation 3m | 89.3% |
| Growth Correlation 12m | -52.8% |
| Growth Correlation 5y | -59.1% |
| CAGR 5y | 12.97% |
| CAGR/Max DD 3y | 0.17 |
| CAGR/Mean DD 3y | 0.37 |
| Sharpe Ratio 12m | 0.70 |
| Alpha | 0.02 |
| Beta | 0.853 |
| Volatility | 69.26% |
| Current Volume | 742.9k |
| Average Volume 20d | 628.5k |
| Stop Loss | 34.8 (-7.1%) |
| Signal | 0.38 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-114.8m TTM) > 0 and > 6% of Revenue (6% = 291.2k TTM) |
| FCFTA -0.24 (>2.0%) and ΔFCFTA -13.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 5017 % (prev 8637 %; Δ -3620 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.27 (>3.0%) and CFO -87.6m > Net Income -114.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 13.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.8m) change vs 12m ago 4.66% (target <= -2.0% for YES) |
| Gross Margin 91.22% (prev 91.74%; Δ -0.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.40% (prev 1.12%; Δ 0.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -10.72
| (A) 0.75 = (Total Current Assets 263.6m - Total Current Liabilities 20.1m) / Total Assets 326.1m |
| (B) -0.72 = Retained Earnings (Balance) -235.5m / Total Assets 326.1m |
| (C) -0.37 = EBIT TTM -130.0m / Avg Total Assets 347.5m |
| (D) -10.24 = Book Value of Equity -235.4m / Total Liabilities 23.0m |
| Total Rating: -10.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.26
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -14.87% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.02 = -2.50 |
| 6. ROIC - WACC (= -48.58)% = -12.50 |
| 7. RoE -34.72% = -2.50 |
| 8. Rev. Trend -11.30% = -0.85 |
| 9. EPS Trend -17.92% = -0.90 |
What is the price of DNTH shares?
Over the past week, the price has changed by +5.34%, over one month by +78.77%, over three months by +105.65% and over the past year by +41.82%.
Is Dianthus Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DNTH is around 34.37 USD . This means that DNTH is currently overvalued and has a potential downside of -8.27%.
Is DNTH a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.5 | 40.1% |
| Analysts Target Price | 52.5 | 40.1% |
| ValueRay Target Price | 38.6 | 2.9% |
Last update: 2025-09-05 04:39
DNTH Fundamental Data Overview
CCE Cash And Equivalents = 257.4m USD (Cash And Short Term Investments, last quarter)
P/S = 160.8752
P/B = 2.5765
Beta = None
Revenue TTM = 4.85m USD
EBIT TTM = -130.0m USD
EBITDA TTM = -129.6m USD
Long Term Debt = 2.90m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 211.0k USD (from shortTermDebt, last quarter)
Debt = 3.12m USD (Calculated: Short Term 211.0k + Long Term 2.90m)
Net Debt = -11.9m USD (from netDebt column, last quarter)
Enterprise Value = 526.6m USD (780.9m + Debt 3.12m - CCE 257.4m)
Interest Coverage Ratio = unknown (Ebit TTM -130.0m / Interest Expense TTM 0.0)
FCF Yield = -14.87% (FCF TTM -78.3m / Enterprise Value 526.6m)
FCF Margin = -1613 % (FCF TTM -78.3m / Revenue TTM 4.85m)
Net Margin = -2364 % (Net Income TTM -114.8m / Revenue TTM 4.85m)
Gross Margin = 91.22% ((Revenue TTM 4.85m - Cost of Revenue TTM 426.0k) / Revenue TTM)
Tobins Q-Ratio = -2.24 (set to none) (Enterprise Value 526.6m / Book Value Of Equity -235.4m)
Interest Expense / Debt = 38.20% (Interest Expense 1.19m / Debt 3.12m)
Taxrate = 21.0% (US default)
NOPAT = -130.0m (EBIT -130.0m, no tax applied on loss)
Current Ratio = 13.12 (Total Current Assets 263.6m / Total Current Liabilities 20.1m)
Debt / Equity = 0.01 (Debt 3.12m / last Quarter total Stockholder Equity 303.1m)
Debt / EBITDA = -0.02 (Net Debt -11.9m / EBITDA -129.6m)
Debt / FCF = -0.04 (Debt 3.12m / FCF TTM -78.3m)
Total Stockholder Equity = 330.5m (last 4 quarters mean)
RoA = -35.19% (Net Income -114.8m, Total Assets 326.1m )
RoE = -34.72% (Net Income TTM -114.8m / Total Stockholder Equity 330.5m)
RoCE = -39.00% (Ebit -130.0m / (Equity 330.5m + L.T.Debt 2.90m))
RoIC = -39.34% (NOPAT -130.0m / Invested Capital 330.5m)
WACC = 9.24% (E(780.9m)/V(784.0m) * Re(9.16%)) + (D(3.12m)/V(784.0m) * Rd(38.20%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 78.79 | Cagr: 22.91%
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -78.3m)
EPS Correlation: -17.92 | EPS CAGR: -6.56% | SUE: -0.24 | # QB: 0
Revenue Correlation: -11.30 | Revenue CAGR: -48.12% | SUE: N/A | # QB: None
Additional Sources for DNTH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle